Novartis envia mensajes sobre el futuro futuro...

Novartis has outlined its long-term strategy for managing a number of key patent expiries.

The Swiss-based pharma firm plans to consolidate its recent acquisitions, but also continue its ‘de-risking’ strategy. It currently faces the patent expiry on its biggest seller Diovan, which made $1.5 billion in the last quarter.

Novartis chief executive Joseph Jimenez, said:

“Novartis has leading businesses in fast growing segments of healthcare, and by focusing on our strategic priorities we are well positioned to succeed in a rapidly changing healthcare environment."

“Novartis remains committed to the core strategy of focused diversification in high-growth healthcare segments. We are leveraging our core competencies in scientific discovery and development to continue driving innovation, growth and productivity across the businesses.”

• focused diversification in high-growth healthcare segments.

• one of the world’s largest ophthalmology specialist

• generics (Sandoz) to “extend its leadership in this area”

• commitment to R&D

• “portfolio rejuvenation” through launches of new medicines

• rely heavily on its recently approved oral MS drug Gilenya

• strengthen its commercial position in emerging markets (BRIC)

Ver